Your browser is no longer supported. Please, upgrade your browser.
Settings
OHRP Ohr Pharmaceutical, Inc. daily Stock Chart
OHRP [NASD]
Ohr Pharmaceutical, Inc.
Index- P/E- EPS (ttm)-0.70 Insider Own2.30% Shs Outstand56.98M Perf Week6.26%
Market Cap36.47M Forward P/E- EPS next Y-1.55 Insider Trans37.46% Shs Float53.46M Perf Month-1.54%
Income-25.20M PEG- EPS next Q- Inst Own13.20% Short Float1.88% Perf Quarter-2.29%
Sales- P/S- EPS this Y-53.60% Inst Trans5.17% Short Ratio5.62 Perf Half Y-39.05%
Book/sh0.52 P/B1.23 EPS next Y-63.20% ROA-85.00% Target Price7.50 Perf Year-75.48%
Cash/sh0.32 P/C2.01 EPS next 5Y- ROE-103.50% 52W Range0.56 - 4.05 Perf YTD-57.33%
Dividend- P/FCF- EPS past 5Y-15.70% ROI- 52W High-84.20% Beta0.05
Dividend %- Quick Ratio3.30 Sales past 5Y- Gross Margin- 52W Low14.02% ATR0.04
Employees14 Current Ratio3.30 Sales Q/Q- Oper. Margin- RSI (14)53.58 Volatility7.38% 5.57%
OptionableYes Debt/Eq0.01 EPS Q/Q70.40% Profit Margin- Rel Volume0.68 Prev Close0.60
ShortableYes LT Debt/Eq0.00 EarningsAug 08 AMC Payout- Avg Volume179.31K Price0.64
Recom2.00 SMA202.02% SMA501.55% SMA200-45.85% Volume121,722 Change6.65%
Oct-27-16Initiated H.C. Wainwright Buy $10
Jun-16-16Resumed ROTH Capital Buy $13
Aug-07-15Reiterated Brean Capital Buy $34 → $30
Mar-30-15Reiterated Chardan Capital Markets Neutral $8 → $3
Mar-27-15Downgrade Chardan Capital Markets Buy → Neutral $20 → $8
Feb-26-15Initiated ROTH Capital Buy $30
Feb-02-15Initiated Chardan Capital Markets Buy $20
Jun-24-14Reiterated Brean Capital Buy $21 → $34
Aug-18-17 08:25AM  TherapeuticsMD (TXMD) Catches Eye: Stock Moves 5.9% Higher Zacks +6.65%
Aug-08-17 04:01PM  Ohr Pharmaceutical Announces Fiscal Third Quarter 2017 Earnings GlobeNewswire
12:10PM  Investor Network: Ohr Pharmaceutical Inc to Host Earnings Call ACCESSWIRE
Jul-31-17 08:00AM  Ohr Pharmaceutical to Announce Fiscal Third Quarter 2017 Results on August 8 GlobeNewswire
Jun-12-17 08:00AM  Ohr Pharmaceutical to Present at the 2017 Marcum Microcap Conference GlobeNewswire
May-11-17 04:15PM  Ohr Pharmaceutical Announces Appointment of Hon. Mike Ferguson as Chairman of the Board of Directors GlobeNewswire
04:01PM  Ohr Pharmaceutical Announces Fiscal Second Quarter 2017 Earnings GlobeNewswire
12:05PM  Investor Network: Ohr Pharmaceutical Inc to Host Earnings Call Accesswire
May-09-17 08:00AM  Ohr Pharmaceutical to Announce Fiscal Second Quarter 2017 Results on May 11 GlobeNewswire
Apr-18-17 08:35AM  Ohr Pharmaceutical (OHRP) Jumps: Stock Adds 15% in Session Zacks -9.64%
Apr-11-17 06:09PM  Ohr Pharmaceutical Provides Update on Squalamine Study Zacks
Apr-10-17 04:15PM  Ohr Pharmaceutical Provides Update on Ongoing Squalamine Clinical Trial in Wet-AMD GlobeNewswire
04:01PM  Ohr Pharmaceutical Announces Closing of Public Offering of Common Stock and Warrants GlobeNewswire
Apr-05-17 09:23AM  Ohr Pharmaceutical Announces Pricing of $14.175 Million Public Offering of Common Stock and Warrants GlobeNewswire -14.29%
09:23AM  Ohr Pharmaceutical Announces Pricing of $14.175 Million Public Offering of Common Stock and Warrants
Apr-04-17 04:01PM  Ohr Pharmaceutical Announces Proposed Public Offering of Common Stock and Warrants GlobeNewswire
04:01PM  Ohr Pharmaceutical Announces Proposed Public Offering of Common Stock and Warrants
Mar-02-17 09:39AM  Ohr Pharmaceutical to Present at the Cowen & Company 37th Annual Health Care Conference GlobeNewswire
Feb-22-17 05:26PM  OHR PHARMACEUTICAL INC Files SEC form 8-K, Other Events
Feb-17-17 01:04PM  OHR PHARMACEUTICAL INC Financials +10.53%
Feb-15-17 03:40PM  The Market Has Got Its Interpretation Of The OHR Pharmaceutical Inc (OHRP) Announcement Wrong Insider Monkey
03:40PM  The Market Has Got Its Interpretation Of The OHR Pharmaceutical Inc (OHRP) Announcement Wrong at Insider Monkey
11:32AM  Ohr Pharmaceutical Reports 4Q Loss, Suspends Trial Investopedia
11:32AM  Ohr Pharmaceutical Reports 4Q Loss, Suspends Trial at Investopedia
Feb-14-17 10:04AM  OHR reports 1Q loss -18.52%
07:07AM  Q1 2017 OHR Pharmaceutical Inc Earnings Release - Before Market Open
07:03AM  OHR PHARMACEUTICAL INC Files SEC form 8-K, Results of Operations and Financial Condition, Other Events
07:00AM  Ohr Pharmaceutical Announces Strategic Update and Fiscal First Quarter 2017 Earnings GlobeNewswire
Feb-13-17 10:32AM  Ohr Pharmaceutical to Announce First Quarter 2017 Financial Results on February 14 GlobeNewswire
Jan-05-17 08:15AM  Post Earnings Coverage as Ohr Pharma Reported Annual Results; Announced Closure of Public Offering Accesswire +6.90%
Dec-27-16 02:35PM  Ohr Pharmaceutical, Inc. :OHRP-US: Earnings Analysis: Q4, 2016 By the Numbers : December 27, 2016 Capital Cube -6.06%
02:35PM  Ohr Pharmaceutical, Inc. :OHRP-US: Earnings Analysis: Q4, 2016 By the Numbers : December 27, 2016
Dec-22-16 05:03PM  OHR PHARMACEUTICAL INC Files SEC form 8-K, Results of Operations and Financial Condition
04:01PM  Ohr Pharmaceutical Reports Fiscal Year 2016 Financial and Business Results GlobeNewswire
07:07AM  Q4 2016 OHR Pharmaceutical Inc Earnings Release - After Market Close
Dec-15-16 02:10PM  Ohr Pharmaceutical to Announce Fourth Quarter and Fiscal 2016 Financial Results on December 22 GlobeNewswire
08:31AM  OHR PHARMACEUTICAL INC Files SEC form 8-K, Regulation FD Disclosure
Dec-14-16 11:30AM  Which Wet AMD Stock Would You Buy Right Now?
08:00AM  Ohr Pharmaceutical Announces Closing of Public Offering of Common Stock and Warrants GlobeNewswire
Dec-13-16 08:22AM  What Fovista's Fail Means For OHR Pharma
Dec-09-16 11:30AM  Ohr Pharmaceuticals Expects $8M from Public Offering at Investopedia
Dec-08-16 05:17PM  OHR PHARMACEUTICAL INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Results of Operations and Fina -24.75%
02:55PM  Ohr Pharma Drops on Secondary Offering
08:00AM  Ohr Pharmaceutical, Inc. Announces Pricing of $7.75 Million Public Offering of Common Stock and Warrants GlobeNewswire
Dec-07-16 04:07PM  Ohr Pharmaceutical Announces Proposed Public Offering of Common Stock and Warrants GlobeNewswire
Oct-30-16 11:06AM  6 Analyst Stock Picks Under $10 For Massive Upside at 24/7 Wall St.
Oct-27-16 12:53PM  Good News And Bad News For Ohr Pharmaceuticals +10.17%
07:05AM  Coverage initiated on Ohr Pharma by H.C. Wainwright
Oct-11-16 08:00AM  Ohr Pharmaceutical to Present at 2016 Ophthalmology Innovation Summit on October 13 GlobeNewswire
Sep-22-16 01:01AM  TiGenix Appoints Dr. June Almenoff to its Board of Directors GlobeNewswire
Sep-20-16 12:18PM  Ohr Pharmaceutical, Inc. :OHRP-US: Earnings Analysis: Q3, 2016 By the Numbers : September 20, 2016
Aug-12-16 09:10AM  OHR PHARMACEUTICAL INC Files SEC form 8-K, Results of Operations and Financial Condition
Aug-09-16 05:20PM  OHR PHARMACEUTICAL INC Files SEC form 10-Q, Quarterly Report +5.43%
05:05PM  OHR reports 3Q loss
04:01PM  Ohr Pharmaceutical Reports Third Quarter 2016 Financial and Business Results GlobeNewswire
07:07AM  Q3 2016 OHR Pharmaceutical Inc Earnings Release - After Market Close
Aug-02-16 08:00AM  Ohr Pharmaceutical to Announce Third Quarter 2016 Financial Results on August 9 GlobeNewswire
Jun-08-16 06:06PM  Ohr Pharmaceutical, Inc. :OHRP-US: Earnings Analysis: Q2, 2016 By the Numbers : June 8, 2016
May-10-16 06:06PM  OHR PHARMACEUTICAL INC Files SEC form 8-K, Results of Operations and Financial Condition
06:02PM  OHR PHARMACEUTICAL INC Files SEC form 10-Q, Quarterly Report
05:18PM  OHR reports 2Q loss
04:01PM  Ohr Pharmaceutical Reports Second Quarter 2016 Financial and Business Results GlobeNewswire
07:07AM  Q2 2016 OHR Pharmaceutical Inc Earnings Release - After Market Close
May-02-16 08:00AM  Ohr Pharmaceutical Announces Appointment of David Brown, MD as Chair of Phase 3 Clinical Program Steering Committee GlobeNewswire
Apr-27-16 08:00AM  Ohr Pharmaceutical Announces Presentations at the 2016 Association for Research in Vision and Ophthalmology (ARVO) Conference in Seattle, WA GlobeNewswire
Apr-26-16 08:00AM  Ohr Pharmaceutical to Announce Second Quarter 2016 Financial Results on May 10 GlobeNewswire
Apr-18-16 08:00AM  Ohr Pharmaceutical, Inc. Announces Enrollment of First Patient in Phase III Wet AMD Clinical Program GlobeNewswire
Apr-13-16 10:39AM  Adobe Systems (ADBE) and Bed Bath & Beyond (BBBY) Witness Insider Selling, While This Pharmaceutical Companys CEO Just Bought Shares at Insider Monkey
Apr-04-16 09:00AM  Biotech Companies That Are Progressing Rapidly Accesswire +8.57%
Mar-30-16 08:00AM  Ohr Pharmaceutical (OHRP) Worth Watching: Stock Up 16.5%
Mar-29-16 04:21PM  OHR PHARMACEUTICAL INC Files SEC form 8-K, Regulation FD Disclosure +16.49%
02:15PM  Ohr Pharma (OHRP) Stock Surges After Launching Phase 3 Trial at TheStreet
09:05AM  OHR Pharmaceutical Gains 7% Following Agreement With FDA
07:13AM  Ohr Pharmaceutical, Inc. Announces SPA Agreement with US FDA and Initiation of Phase III Wet AMD Clinical Program at noodls
07:00AM  Ohr Pharmaceutical, Inc. Announces SPA Agreement with US FDA and Initiation of Phase III Wet AMD Clinical Program GlobeNewswire
Mar-21-16 04:22PM  OHR PHARMACEUTICAL INC Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a Vote
Mar-02-16 02:46PM  Ohr Pharmaceutical to Present at Upcoming Investment Conferences GlobeNewswire +7.56%
Feb-24-16 07:16AM  8 Stocks Under $10 Making Big Moves Higher at TheStreet
Feb-17-16 03:15PM  Flexion's (FLXN) Pain Drug Zilretta Tops Phase III Study +5.65%
09:00AM  RedHill Biopharma Appoints Dr. June S. Almenoff and Ms. Theresa M. Stevens to Advisory Board GlobeNewswire
Feb-10-16 09:01AM  OHR PHARMACEUTICAL INC Files SEC form 8-K, Results of Operations and Financial Condition
Feb-09-16 05:14PM  OHR PHARMACEUTICAL INC Files SEC form 10-Q, Quarterly Report
04:41PM  OHR reports 1Q loss
04:01PM  Ohr Pharmaceutical Reports First Quarter 2016 Financial and Business Results GlobeNewswire
09:49AM  Ohr Pharmaceutical to Present at the LEERINK Partners 5th Annual Global Healthcare Conference in New York GlobeNewswire
07:07AM  Q1 2016 OHR Pharmaceutical Inc Earnings Release - After Market Close
Feb-03-16 08:00AM  Ohr Pharmaceutical to Announce First Quarter 2016 Financial Results on February 9 GlobeNewswire -5.66%
Feb-02-16 04:40PM  Jazz's Phase III Data on Defibrotide Published in ASH Journal -5.60%
Jan-21-16 11:35AM  CEO Invests in Ohr Pharmaceutical
Jan-19-16 09:30AM  The Zacks Analyst Blog Highlights: Aerie Pharmaceuticals, United Therapeutics, Pacira Pharmaceuticals, Ohr Pharmaceutical and Infinity Pharmaceuticals -8.09%
Dec-14-15 05:00PM  OHR PHARMACEUTICAL INC Files SEC form 10-K, Annual Report
Dec-10-15 04:04PM  OHR PHARMACEUTICAL INC Files SEC form 8-K, Results of Operations and Financial Condition
04:01PM  Ohr Pharmaceutical Reports Fiscal Year 2015 Financial and Business Results GlobeNewswire
07:07AM  Full Year 2015 OHR Pharmaceutical Inc Earnings Release - After Market Close
Dec-08-15 08:11AM  RDD Pharma Appoints Dr. June Almenoff as Board Chairman PR Newswire
08:00AM  Ohr Pharmaceutical to Report Fiscal 2015 Financial Results on Thursday, December 10 GlobeNewswire
Dec-04-15 09:34AM  OHR Pharmaceutical (OHRP) Shares March Higher, Can It Continue?
Dec-03-15 08:00AM  Ohr Pharmaceutical Announces Positive Preclinical Data in SKS Sustained Release Ocular Program GlobeNewswire
Nov-25-15 02:32PM  Can OHR Pharmaceutical Inc (OHRP)s Run Continue? at Insider Monkey +20.15%
Nov-24-15 06:23AM  Hedge Funds Are Abandoing Pain Therapeutics, Inc. (PTIE) at Insider Monkey
OHR Pharmaceutical, Inc., a pharmaceutical company, focuses on the development of novel therapeutics and delivery technologies for the treatment of ocular disease. Its lead clinical program is topical Squalamine, a small molecule anti-angiogenic drug, which could provide a non-invasive therapy to enhance vision outcomes. The company is evaluating Squalamine, which completed Phase II clinical trials for the treatment of retinal diseases, including wet-AMD, proliferative diabetic retinopathy, and retinal vein occlusion. Its preclinical pipeline of sustained release programs include sustained release formulations of small molecule and protein therapeutics for the treatment of ocular diseases, such as glaucoma, steroid induced glaucoma, ocular allergy, and retinal disease. OHR Pharmaceutical, Inc. is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Slakter Jason ScottChief Executive OfficerApr 10Buy0.70142,858100,0011,067,898Apr 13 02:45 PM
HIRSCHMAN ORINDirectorApr 10Buy0.70142,858100,0011,649,605Apr 13 11:11 AM
Backenroth SamuelChief Financial OfficerApr 10Buy0.7071,42950,000212,596Apr 13 12:59 PM